Overview

Colchicine to Reduce Your SympToms and Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (CPPD) disease. The trial will also test the effect of colchicine on joint symptoms in CPPD disease. The main questions it aims to answer are: * Does colchicine reduce the level of interleukin 18 (IL-18) in the blood of individuals with CPPD disease? * Does colchicine reduce pain scores in individuals with CPPD disease? Researchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat CPPD disease. Participants will: * Take colchicine or a placebo every day for 6 months * Visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. Each visit will last 2-3 hours. * Speak on the telephone with researchers for about 4 times over 6 months. Each phone call will last about 5 minutes.

Phase:

PHASE2

Details

Lead Sponsor:

Brigham and Women's Hospital

Collaborator:

Rheumatology Research Foundation

Treatments:

Colchicine